Galectin Therapeutics Inc. Common Stock (GALT)

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hyperte…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

9

Website

galectintherapeutics.com

Fundamentals

1-day range

$3.2$3.55

Market cap

$324.74M

P/E (trailing)

—

P/E (forward)

-2.05

EPS (trailing)

$-0.43

Dividend yield

—

Beta

—

Avg. volume

662.4K

Forecasts

1 analyst ratings

Galectin Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• GALT

  Galectin Therapeutics Inc. Common Stock

  $4.02

  ▼ 2.90%
  Market cap $324.74MP/E —
  $2.03$7.13
• FHTX

  Foghorn Therapeutics Inc. Common Stock

  $6

  ▼ 3.54%
  Market cap $327.04MP/E —
• CATX

  Perspective Therapeutics Inc. Common Stock

  $3.1

  ▼ 2.67%
  Market cap $338.72MP/E —
  $1.96$6.16
• ORGO

  Organogenesis Holdings Inc. Class A Common Stock

  $1.74

  ▼ 0.00%
  Market cap $310.11MP/E 84.95
  $1.54$7.08
• VNDA

  Vanda Pharmaceuticals Inc. Common Stock

  $5.29

  ▼ 2.76%
  Market cap $307.59MP/E —
  $4.27$9.94
• IRD

  Opus Genetics Inc. Common Stock

  $3.7

  ▼ 3.90%
  Market cap $307.14MP/E —
  $1.17$5.81
• ZNTL

  Zentalis Pharmaceuticals Inc. Common Stock

  $3.8

  ▼ 2.06%
  Market cap $355.93MP/E —
  $1.21$6.95

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
  Yahoo · 8/14/2026
• Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
  Benzinga · 8/14/2026
• Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
  Yahoo · 8/4/2026
• 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  Benzinga · 8/4/2026
• Galectin Therapeutics Converts ~$105.8M Of Debt Into ~34.4M Shares At Blended Average Conversion Price Of ~$3.07 Per Share
  Benzinga · 8/4/2026

• Richard E. Uihlein · July 31, 2026 · Option Exercise

  0 @ $95,475,704
• Richard E. Uihlein · July 31, 2026 · Option Exercise

  2.55M @ $4.05
• Richard E. Uihlein · July 31, 2026 · Option Exercise

  31.83M @ $3
• Khurram Jamil · July 14, 2026 · Option Exercise

  16.3K @ $3.04
• Khurram Jamil · July 14, 2026 · Sale

  16.3K @ $5.13
• Khurram Jamil · June 23, 2026 · Option Exercise

  7.6K @ $1.23
• Khurram Jamil · June 23, 2026 · Sale

  7.6K @ $3.14
• Khurram Jamil · May 26, 2026 · Option Exercise

  568 @ $1.23
• Khurram Jamil · May 26, 2026 · Sale

  568 @ $3.1
• Brem Henry · March 12, 2026 · Grant

  60.0K

Institutional Ownership

March 31, 2026

Total shares held

15.14M

Total value held

$41.35M

Institutional holders

97